IP Library Granted Patent US 8,035,809
Granted Patent B2
US 8,035,809 · App. 12/325,353 · Granted Oct 11, 2011

Bubble removal system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,035,809
App. No.
12/325,353
Granted
Oct 11, 2011
Kind
B2
Abstract

A bubble removal system includes an inspection cell configured to receive an ophthalmic device and a volume of working fluid. The system also includes a vacuum device configured to form a substantially fluid-tight seal with the inspection cell and to direct a negative pressure to the volume of working fluid and the ophthalmic device within the inspection cell.

Claims (34)

1. A bubble removal system, comprising:

an inspection cell configured to receive an ophthalmic device and a volume of working fluid; and

a vacuum device configured to form a substantially fluid-tight seal with the inspection cell and to direct a negative pressure to the volume of working fluid and the ophthalmic device within the inspection cell, wherein the vacuum device comprises a head defining at least one channel, a piston and an arm, a portion of the piston being disposed within the at least one channel.

2. The system of claim 1 , wherein a component of the vacuum device is controllably moveable relative to the inspection cell to assist in forming the substantially fluid-tight seal.

3. The system of claim 1 , wherein the inspection cell is a component of an inspection station disposed upstream of a packaging station.

4. The system of claim 1 , wherein the vacuum device is configured to assist in removing at least one bubble defined by the working fluid.

5. The system of claim 1 , wherein the vacuum device is configured to assist in bringing a portion of the working fluid to a boil.

6. The system of claim 1 , wherein the vacuum device is configured to assist in defining a sealed region of the inspection cell, the sealed region containing ambient air disposed adjacent to a surface of the working fluid.

7. The system of claim 6 , wherein the vacuum device is configured to assist in substantially evacuating the ambient air from the sealed region.

8. The system of claim 6 , wherein the vacuum device is configured to reduce a pressure of the sealed region below a vapor pressure of the working fluid.

9. The system of claim 1 , wherein the head is connected to an actuation assembly configured to control the position of the head relative to the inspection cell.

10. The system of claim 1 , wherein the vacuum device further comprises a vacuum line and a compressor, the vacuum line being fluidly connected to the at least one channel.

11. The system of claim 1 , wherein the portion of the piston forms a substantially fluid-tight seal with the at least one channel.

12. A method of removing bubbles formed in a volume of working fluid, comprising:

disposing an ophthalmic device within the volume of working fluid, the volume of working fluid being contained within an inspection cell;

forming a sealed region between the inspection cell and a vacuum device;

directing a negative pressure to the sealed region with the vacuum device which includes increasing a volume of the sealed region; and

removing at least one bubble from the volume of working fluid.

13. The method of claim 12 , wherein the at least one bubble is adhered to the ophthalmic device.

14. The method of claim 12 , wherein directing the negative pressure to the sealed region includes bringing a portion of the working fluid to a boil.

15. The method of claim 12 , further including trapping ambient air in the sealed region and substantially evacuating the ambient air from the sealed region.

16. The method of claim 12 , wherein directing the negative pressure to the sealed region includes increasing a dimension of the at least one bubble.

17. The method of claim 12 , wherein increasing the volume of the sealed region includes transitioning a piston of the vacuum device from an extended position to a retracted position, the piston forming a portion of the sealed region.

18. A method of preparing a volume of working fluid for the inspection of an ophthalmic device, comprising:

substantially submerging the ophthalmic device in the working fluid;

reducing a pressure of the working fluid below an ambient pressure;

bringing a portion of the working fluid to a boil;

increasing the pressure of the working fluid to the ambient pressure; and

sensing at least one characteristic of the ophthalmic device while the ophthalmic device is substantially submerged in the working fluid.

19. The method of claim 18 , further including defining a sealed region, the sealed region containing the working fluid and a pocket of ambient air disposed adjacent to a surface of the working fluid.

20. The method of claim 18 , further including packaging the ophthalmic device based on the sensing of the at least one characteristic.

21. The method of claim 18 , further including removing at least one bubble from the working fluid.

22. The method of claim 18 , wherein reducing the pressure of the working fluid includes defining a sealed region containing the working fluid and increasing a volume of the sealed region.

23. The method of claim 22 , wherein increasing the volume of the sealed region includes transitioning a piston of a vacuum device from an extended position to a retracted position, the piston forming a portion of the sealed region.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Oct 28, 2011
From: BAUSCH & LOMB INCORPORATED
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
Reel/Frame 027143/0860 →